Publications by authors named "Marius Ardeleanu"

Claim this Profile
S
Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry.
Amy S Paller, Danielle Marcoux, Michele Ramien, Eulalia Baselga, Vania Oliveira Carvalho, Marius Ardeleanu

Am J Clin Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults.
Richard G Langley, Guy Gherardi, Anna Coleman, Marius Ardeleanu, Ainara Rodríguez-Marco

Am J Clin Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Commentary: Response to "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study".
Tien V Nguyen, Andrea Fleisch Marcus, Sarah-Jo Sinnott, Anna Coleman, Carlos Peralta, Marius Ardeleanu

J Am Acad Dermatol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDIatric STudy in Atopic Dermatitis.
Amy S Paller, Marjolein de Bruin-Weller, Danielle Marcoux, Eulalia Baselga, Vania Oliveira de Carvalho, Marius Ardeleanu

J Am Acad Dermatol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis.
Piergiacomo Calzavara-Pinton, Chia-Yu Chu, Hilde Lapeere, Mariateresa Rossi, Silvia M Ferrucci, Marius Ardeleanu

Adv Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved sleep parallels improvements in atopic dermatitis signs, symptoms, and quality of life in adult patients treated with dupilumab: 24-week results from the DUPISTAD study.
Joseph F Merola, Albert S Chiou, Emmanuel During, Peter Foley, Jiangming Wu, Marius Ardeleanu

J Am Acad Dermatol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review).
Victoria P Werth, Dédée F Murrell, Pascal Joly, Renata Heck, Jamie M Orengo, Marius Ardeleanu

Adv Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis.
Mohamed A Kamal, Matthew P Kosloski, Ching-Ha Lai, Michael A Partridge, Manoj Rajadhyaksha, Marius Ardeleanu

Front Immunol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation Analysis of Clinician- and Patient-Reported Outcomes Among Japanese Adults with Atopic Dermatitis.
Hidehisa Saeki, Yoko Kataoka, Takafumi Etoh, Norito Katoh, Satoshi Teramukai, Marius Ardeleanu

Dermatol Ther (Heidelb)· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Demographics, Comorbidities, Treatment Patterns and Burden of Atopic Dermatitis in Adults and Adolescents from the GLOBOSTAD Long-Term Observational Study.
Piergiacomo Calzavara-Pinton, Jarmila Čelakovská, Hilde Lapeere, Gregor Holzer, Mona Al-Ahmad, Marius Ardeleanu

Adv Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study.
Joseph F Merola, Albert S Chiou, Emmanuel During, Antonio Costanzo, Peter Foley, Marius Ardeleanu

Br J Dermatol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attenuating the atopic march: Meta-analysis of the dupilumab atopic dermatitis database for incident allergic events.
Gregory P Geba, Dateng Li, Meng Xu, Kusha Mohammadi, Richa Attre, Marius Ardeleanu

J Allergy Clin Immunol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics, and exposure-efficacy of dupilumab in adults with atopic dermatitis.
Mohamed A Kamal, John D Davis, Pavel Kovalenko, Kamal Srinivasan, Eric L Simpson, Marius Ardeleanu

Clin Transl Sci· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of standard treatments for managing adult Japanese patients with inadequately controlled moderate-to-severe atopic dermatitis: Two-year data from the ADDRESS-J disease registry.
Norito Katoh, Hidehisa Saeki, Yoko Kataoka, Takafumi Etoh, Satoshi Teramukai, Marius Ardeleanu

J Dermatol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD).
Marjolein de Bruin-Weller, Andrew E Pink, Silvia M Ferrucci, Annalisa Patrizi, Ake Svensson, Marius Ardeleanu

J Dermatolog Treat· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases.
G Walter Canonica, Arnaud Bourdin, Anju T Peters, Martin Desrosiers, Claus Bachert, Marius Ardeleanu

J Allergy Clin Immunol Pract· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE).
Jerry Bagel, Tien Q Nguyen, Hermenio Lima, Neal Jain, David M Pariser, Marius Ardeleanu

Dermatol Ther (Heidelb)· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year.
Andrew Blauvelt, Marjolein de Bruin-Weller, Eric L Simpson, Zhen Chen, Marius Ardeleanu

Dermatol Ther (Heidelb)· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials.
Jonathan I Silverberg, Eric L Simpson, Emma Guttman-Yassky, Michael J Cork, Marjolein de Bruin-Weller, Marius Ardeleanu

Dermatitis· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.
Jennifer D Hamilton, Sivan Harel, Brian N Swanson, William Brian, Zhen Chen, Marius Ardeleanu

Clin Exp Allergy· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis.
Mark Boguniewicz, Lisa A Beck, Lawrence Sher, Emma Guttman-Yassky, Diamant Thaçi, Marius Ardeleanu

J Allergy Clin Immunol Pract· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study.
Marjolein de Bruin-Weller, Andrew E Pink, Annalisa Patrizi, Ana M Gimenez-Arnau, Tove Agner, Marius Ardeleanu

J Dermatolog Treat· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A basophil-neuronal axis promotes itch.
Fang Wang, Anna M Trier, Fengxian Li, Seonyoung Kim, Zhen Chen, Marius Ardeleanu

Cell· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Ashish Bansal, Eric L Simpson, Amy S Paller, Elaine C Siegfried, Andrew Blauvelt, Marius Ardeleanu

Am J Clin Dermatol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Lisa A Beck, Diamant Thaçi, Mette Deleuran, Andrew Blauvelt, Robert Bissonnette, Marius Ardeleanu

Am J Clin Dermatol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis